Original articleThe REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity
Section snippets
Methods
The REDUCE Pivotal Trial was a prospective, sham-controlled, double-blinded, randomized multicenter clinical study that enrolled patients between August 13, 2012 and February 18, 2013. Participants were between the ages of 21 and 60 years of age with a baseline body mass index (BMI) of≥30 kg/m2 and≤40 kg/m2 with one or more obesity-related co-morbid conditions who provided written informed consent, were not at risk of pregnancy, and had failed to lose weight within the prior 36 months with a
Results
A total of 326 consented patients (187 DUO, 139 DIET) were randomized between August 13, 2012 and February 18, 2013 at 8 U.S. academic and community practice sites. Ninety percent (167 DUO patients and 126 DIET) of patients completed the 24 week randomized assessment period and all were assessed for primary endpoints as randomized. One-hundred-thirty-six (136) DUO patients went on to complete Weeks 24–48 of posttreatment follow-up for assessment of weight loss maintenance, and 77 DIET patients
Discussion
Novel treatments are needed to fill the treatment gap in obesity interventions [26]. Conventional therapies with diet and exercise have modest treatment effects and low compliance. Pharmacotherapy may be somewhat more effective, but to date has been hampered by cost, compliance failures, and concerns regarding adverse effects and the potential for congenital defects; the latter is a major concern given the preponderance of women of childbearing age in the target population. Bariatric surgery
Conclusion
The REDUCE Pivotal Trial of the ReShape Duo® Integrated Dual Balloon System in the treatment of patients with obesity demonstrated that the dual balloon is significantly more effective than diet and exercise alone in causing weight loss with a low adverse event profile. Treatment with the dual balloon supports diet compliance through 24 weeks, potentially allowing patients to relearn eating and exercise habits while undergoing an effective, low risk, reversible treatment with demonstrated
Disclosures
J. Ponce: ReShape Medical: consulting fees, funding for clinical research
G. Woodman: ReShape Medical: funding for clinical research
J. Swain: ReShape Medical: funding for clinical research
E. Wilson: ReShape Medical: funding for clinical research
W. English: ReShape Medical: funding for clinical research
S. Ikramuddin: ReShape Medical: funding for clinical research
E. Bour: ReShape Medical: funding for clinical research
S. Edmundowicz: ReShape Medical: funding for clinical research; GI Dynamics:
Acknowledgments
The Clinical Events and Data Monitoring Committee members were: Sreeni Jonnalagadda, M.D., FASGE (Chair), University of Missouri at Kansas City, Garth Jacobsen, M.D., FACS, UCSD Medical Center, Peter Denk, M.D., F.A.C.S., GI Surgical Specialists, PLLC, and Richard Chiacchierini, Ph.D., R. P. Chiacchierini & Associates, LLC. The REDUCE Pivotal Trial was supported financially by ReShape Medical. Monitoring was provided by ReShape Medical, Inc. with support from NAMSA (North American Science
References (30)
- et al.
Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up
Gastrointest Endosc
(2005) - et al.
Assessment of blinding in clinical trials
Control Clin Trials
(2004) - et al.
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial
Lancet
(2010) Evidence-based review of the BioEnterics intragastric balloon for weight loss
Obes Surg
(2008)- et al.
Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis
Obes Surg
(2008) - et al.
Prospective, randomized, multicenter study evaluating safety and efficacy of intragastric dual-balloon in obesity
Surg Obes Relat Dis
(2012) - et al.
BioEnterics Intragastric Balloon (BIB): a short term, double blind, randomized, controlled crossover study on weight reduction in morbidly obese patients
Int J Obes
(2006) - et al.
Intragastric balloon-induced satiety is not mediated by modification in fasting or postprandial plasma ghrelin levels in morbid obesity
Obes Surg.
(2007) - et al.
Fasting and meal-induced CCK and PP secretion following intragastric balloon treatment for obesity
Obes Surg.
(2013) - et al.
500 Intragastric Balloons: What Happens 5 Years Thereafter?
Obes Surg
(2012)
BioEnterics® intragastric balloon (BIB®). Single ambulatory center Spanish experience with 714 consecutive patients treated with one or two consecutive balloons
Obes Surg
Impact on obesity-related illnesses and quality of life following intragastric balloon
Obes Surg
Multi-centre European experience with intragastric balloon in overweight populations: 13 years of experience
Obes Surg
Single vs repeated treatment with the intragastric balloon: a 5-year weight loss study
Obes Surg
Intragastric balloon followed by diet vs intragastric balloon followed by another balloon: a prospective study on 100 patients
Obes Surg
Cited by (185)
Randomized Double-blind Sham-controlled Trial of a Novel Silicone-filled Endoscopically Placed Device for Weight Loss
2024, Techniques and Innovations in Gastrointestinal EndoscopyDisparities in Access and Quality of Obesity Care
2023, Gastroenterology Clinics of North AmericaGastroscope-assisted laparoscopic sleeve gastrectomy: A case report with an unexpected old deflated intragastric balloon
2022, International Journal of Surgery Case ReportsClinical efficacy and mechanism of action of medical devices for obesity and type 2 diabetes
2022, Current Opinion in Endocrine and Metabolic Research